Physician profile
Jeffrey Goodman
NPI 1700846037
$1,140.54
in general payments reported to CMS, 2019-2025
14 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2021: $124 · 2022: $125 · 2023: $178 · 2024: $53.88 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $411.92 | 2019-2025 | Lens 4k, Double Pump Rf, Pico |
| Pacira Therapeutics, INC. | $117.42 | 2019-2021 | |
| Horizon Therapeutics Plc | $99.66 | 2019-2023 | Krystexxa |
| Zimmer Biomet Holdings, INC. | $89.46 | 2022-2025 | Gel-One Cross-Linked Hyaluronate |
| Abbvie INC. | $72.60 | 2021-2022 | |
| Heraeus Medical, LLC. | $66.81 | 2019 | |
| Ferring Pharmaceuticals INC. | $66.49 | 2025 | Euflexxa |
| Kerecis Limited | $63.23 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Bioventus LLC | $38.53 | 2022-2024 | Exogen Ultrasound Bone Healing System |
| Depuy Synthes Sales INC. | $37.23 | 2023 | Monovisc |
| Pacira Pharmaceuticals Incorporated | $24.98 | 2025 | Exparel, Iovera, Zilretta |
| Mallinckrodt Enterprises LLC | $20.23 | 2019 | |
| Stimlabs LLC | $16.75 | 2025 | Corplex P |
| Sanofi-Aventis U.S. LLC | $15.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.